Elvira P. Kasatkina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elvira P. Kasatkina has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Goar Feliksovna Okminyan
Russian Medical Academy of Continuous Professional Education
9 shared publications - Oleg Yu. Latyshev
Russian Medical Academy of Continuous Professional Education
8 shared publications - Elena Valentinovna Kiseleva
Russian Medical Academy of Continuous Professional Education
7 shared publications - Lubov Nikolaevna Samsonova
Russian Medical Academy of Continuous Professional Education
7 shared publications Russian Medical Academy Of Continuing Professional Education
5 shared publications- Mikhail Ivanovich Pykov
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
4 shared publications
Latest Publications
- 1 January 2021
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 10 (2)
Flash glucose monitoring in the practice of pediatric endocrinologist
- 1 January 2021
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 10 (2)
Flash glucose monitoring in the practice of pediatric endocrinologist
- 1 January 2021
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 10 (2)
Clinical and laboratory characteristics of constitutional delayed puberty in girls
- 1 January 2021
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 10 (2)
Clinical and laboratory characteristics of constitutional delayed puberty in girls
- 1 January 2021
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 10 (1)
Basal insulin evolution: from simple to more complex
Эволюция препаратов базального инсулина: от простого к сложному
- 1 January 2021
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 10 (1)
Basal insulin evolution: from simple to more complex
Эволюция препаратов базального инсулина: от простого к сложному
- Open Access
- 6 February 2020
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 65 (6) , 417-424
The differential diagnosis of constitutional delay of puberty and hypogonadotropic hypogonadism in boys
Backgraund: The problem of differential diagnosis of constitutional delay of puberty/CPD and hypogonadotropic hypogonadism/HH in boys is discussed, as boys have similar genetic mechanisms and appearance. Aims: to determine accuracy of the criteria for the differential diagnosis of CDP and HH. Materials: The study included 56 boys14,40,7 years old with delayed puberty (G1P1-3/testicular volume 3сm3). We excluded patients with hypergonadotropic hypogonadism, treated with sex steroids or gonadotropins for 12 months, with endocrine/somatic diseases affecting puberty. At the first visit, we evaluated anthropometric data, bone age, testicular volume, hormones and the results of the gonadotropin-releasing hormone test/GnRH agonist test and the human chorionic gonadotropin test/hCG test. The HH was defined by a testicular volume 3сm3 after 2 years follow-up. The patients were divided into two groups: the first group with CDP and testicles 3cm3 (n=50) and the second group with HH and testicles 3cm3 (n=6). Results: At the first visit in boys with CDP corrected target height was less (Me SDS -1,8 vs -0,4, р=0,02), bone age was less (Ме SDS -2,5 vs - 0,2 р=0,03), testicular volume was more (Ме 1,9 vs 0,5, p=0,0003), hormones were significantly higher, such as, LH (Ме 1,1 vs 0,1mIU/ml, p=0,0002), FSH (Ме 1,9 vs 0,2IU/l, p=0,00007), inhibinB (Ме 142,3 vs 31,3pg/ml, p=0,00009), maxLH (Ме 18,9 vs 0,6mIU/ml, p=0,00007), maxLH/FSH (Ме 2,3 vs 0,4, p=0,0002) on the GnRH agonist test and testosterone (Ме 14,4 vs 1,1nmol/l, p=0,0001) on the hCG test than in boys with HH. The LH 0,3 mIU/ml had 86% sensitivity, 100% specificity; maxLH/FSH1- 92% sensitivity, 100% specificity; testosterone 2,7 nmol/l on the hCG test - 98% sensitivity, 100% specificity for differential diagnosis of CDP and HH in boys. However, maxLH 3,5 mIU/ml on the GnRH agonist test, FSH 0,5 IU/l, inhibinB 58 pg/ml had 100% sensitivity and specificity for diagnosis of CDP. Conclusions: The inhibinB 58 pg/ml, LH 0,3 mIU/ml, FSH 0,5 IU/l or maxLH 3,5 mIU/ml, maxLH/FSH 1,0 on the GnRH agonist test, testosterone 2,7 nmol/l on the hCG test have an excellent accuracy for the differential diagnosis of CDP and HH in prepubertal boys with delayed puberty.
- 6 February 2020
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 65 (6) , 417-424
Open AccessThe differential diagnosis of constitutional delay of puberty and hypogonadotropic hypogonadism in boys
Backgraund: The problem of differential diagnosis of constitutional delay of puberty/CPD and hypogonadotropic hypogonadism/HH in boys is discussed, as boys have similar genetic mechanisms and appearance. Aims: to determine accuracy of the criteria for the differential diagnosis of CDP and HH. Materials: The study included 56 boys14,40,7 years old with delayed puberty (G1P1-3/testicular volume 3сm3). We excluded patients with hypergonadotropic hypogonadism, treated with sex steroids or gonadotropins for 12 months, with endocrine/somatic diseases affecting puberty. At the first visit, we evaluated anthropometric data, bone age, testicular volume, hormones and the results of the gonadotropin-releasing hormone test/GnRH agonist test and the human chorionic gonadotropin test/hCG test. The HH was defined by a testicular volume 3сm3 after 2 years follow-up. The patients were divided into two groups: the first group with CDP and testicles 3cm3 (n=50) and the second group with HH and testicles 3cm3 (n=6). Results: At the first visit in boys with CDP corrected target height was less (Me SDS -1,8 vs -0,4, р=0,02), bone age was less (Ме SDS -2,5 vs - 0,2 р=0,03), testicular volume was more (Ме 1,9 vs 0,5, p=0,0003), hormones were significantly higher, such as, LH (Ме 1,1 vs 0,1mIU/ml, p=0,0002), FSH (Ме 1,9 vs 0,2IU/l, p=0,00007), inhibinB (Ме 142,3 vs 31,3pg/ml, p=0,00009), maxLH (Ме 18,9 vs 0,6mIU/ml, p=0,00007), maxLH/FSH (Ме 2,3 vs 0,4, p=0,0002) on the GnRH agonist test and testosterone (Ме 14,4 vs 1,1nmol/l, p=0,0001) on the hCG test than in boys with HH. The LH 0,3 mIU/ml had 86% sensitivity, 100% specificity; maxLH/FSH1- 92% sensitivity, 100% specificity; testosterone 2,7 nmol/l on the hCG test - 98% sensitivity, 100% specificity for differential diagnosis of CDP and HH in boys. However, maxLH 3,5 mIU/ml on the GnRH agonist test, FSH 0,5 IU/l, inhibinB 58 pg/ml had 100% sensitivity and specificity for diagnosis of CDP. Conclusions: The inhibinB 58 pg/ml, LH 0,3 mIU/ml, FSH 0,5 IU/l or maxLH 3,5 mIU/ml, maxLH/FSH 1,0 on the GnRH agonist test, testosterone 2,7 nmol/l on the hCG test have an excellent accuracy for the differential diagnosis of CDP and HH in prepubertal boys with delayed puberty.
- 1 January 2020
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 9 (3)
Puberty delay in girls: etiologic structure of the disease
- 1 January 2020
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 9 (3)
Puberty delay in girls: etiologic structure of the disease
- 1 January 2020
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 9 (2) , 80-85
Current tendencies in treatment of congenital hypogonadotropic hypogonadism in boys: clinical cases’ analysis
Current tendencies in treatment of congenital hypogonadotropic hypogonadism in boys: clinical cases’ analysis
- 1 January 2020
- Published by Geotar-Media Publishing Group in Endocrinology: News, Opinions, Training
- Vol. 9 (2) , 80-85
Current tendencies in treatment of congenital hypogonadotropic hypogonadism in boys: clinical cases’ analysis
Current tendencies in treatment of congenital hypogonadotropic hypogonadism in boys: clinical cases’ analysis
- Open Access
- 4 May 2017
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 63 (2) , 124-126
De la Chapelle syndrome: clinical and laboratory characteristics of 4 patients
We describe 4 cases of 46,XX testicular disorder of sex development. Depending on the presence of the SRY gene, two variants of this disease are distinguished: SRY-positive and SRY-negative ones. The SRY (sex-determining region Y) gene is involved in differentiation of Sertoli cells and development of the testes. The pathogenesis of the disease in SRY-positive patients is related to translocation of the SRY gene from the Y chromosome to the X chromosome. The pathogenesis of the disease in SRY-negative patients is associated with overexpression of genes (SOX9, SOX3, etc.) responsible for the development of male genitalia or inadequate gene expression (WNT4, RSPO1, etc.) responsible for the development of female genitalia. The patients had a hermaphroditic genital structure with a masculinization score (EMS) of 6 and 11 and were SRY-negative in 50% of cases; 50% of the patients were SRY-positive with full masculinization, microorchidism, and gynecomastia. All children underwent a hormonal examination in the neutral and pubertal periods. Patients who reached pubertal age developed partial and total hypergonadotropic hypogonadism. The patients have had no need in substitution therapy with testosterone. One of the patients underwent a semiological analysis that revealed necrozoospermia and oligoasthenoteratozoospermia. A SRY-negative patient with cryptorchidism underwent biopsy of the cryptorchid gonad; no Leydig cells were found.
- 4 May 2017
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 63 (2) , 124-126
Open AccessDe la Chapelle syndrome: clinical and laboratory characteristics of 4 patients
We describe 4 cases of 46,XX testicular disorder of sex development. Depending on the presence of the SRY gene, two variants of this disease are distinguished: SRY-positive and SRY-negative ones. The SRY (sex-determining region Y) gene is involved in differentiation of Sertoli cells and development of the testes. The pathogenesis of the disease in SRY-positive patients is related to translocation of the SRY gene from the Y chromosome to the X chromosome. The pathogenesis of the disease in SRY-negative patients is associated with overexpression of genes (SOX9, SOX3, etc.) responsible for the development of male genitalia or inadequate gene expression (WNT4, RSPO1, etc.) responsible for the development of female genitalia. The patients had a hermaphroditic genital structure with a masculinization score (EMS) of 6 and 11 and were SRY-negative in 50% of cases; 50% of the patients were SRY-positive with full masculinization, microorchidism, and gynecomastia. All children underwent a hormonal examination in the neutral and pubertal periods. Patients who reached pubertal age developed partial and total hypergonadotropic hypogonadism. The patients have had no need in substitution therapy with testosterone. One of the patients underwent a semiological analysis that revealed necrozoospermia and oligoasthenoteratozoospermia. A SRY-negative patient with cryptorchidism underwent biopsy of the cryptorchid gonad; no Leydig cells were found.
- Open Access
- 4 May 2017
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 63 (2) , 103-105
Growth and sexual retardation in a boy with celiac disease
Growth and sexual retardation in boys can be caused by both endocrine and somatogenic causes. One of the somatogenic causes of growth and puberty retardation is celiac disease that is a genetic disorder of the small intestine, which is associated with deficiency of enzymes breaking down the gluten peptide. The clinical picture of celiac disease may be dominated by gastrointestinal manifestations (diarrhea, recurrent abdominal pain, nausea, constipation, appetite disorders) and nonspecific symptoms (irritability, apathy, physical and sexual retardation, impaired reproductive function, anemia, etc.). We present a case of late diagnosis of celiac disease in a 15-year-old boy with physical (height SDS, -4.1; bone age SDS, -8.2) and sexual (Tanner 1) retardation. The negative results of gonadoliberin (max LH, 2 mIU/mL) and chorionic gonadotropin (Δ-testosterone, 2,3 nmol/L) tests indicated the lack of activation of the hypothalamo-pituitary-gonadal system. However, inhibin B (29.9 pg/mL) and anti-Mullerian hormone (43.8 ng/mL) levels indicated preservation of the reserve capabilities of this system. During follow-up, after treatment with a gluten-free diet for 10 months, the patient demonstrated an improved growth rate (2.7 SDS), progression of the sexual development stage (Tanner 2), and positive results of diagnostic diphereline (max LH, 16.8 IU/mL) and chorionic gonadotropin (Δ-testosterone, 11.8 nmol/L) tests. This case demonstrates the need to exclude celiac disease in patients with growth and sexual retardation, especially when these pathologies are combined with protein-energy deficiency, gastrointestinal symptoms, and anemia, as well as the need to use additional indicators of the reproductive system condition in boys, e.g. inhibin B and anti-Mullerian hormone.
- 4 May 2017
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 63 (2) , 103-105
Open AccessGrowth and sexual retardation in a boy with celiac disease
Growth and sexual retardation in boys can be caused by both endocrine and somatogenic causes. One of the somatogenic causes of growth and puberty retardation is celiac disease that is a genetic disorder of the small intestine, which is associated with deficiency of enzymes breaking down the gluten peptide. The clinical picture of celiac disease may be dominated by gastrointestinal manifestations (diarrhea, recurrent abdominal pain, nausea, constipation, appetite disorders) and nonspecific symptoms (irritability, apathy, physical and sexual retardation, impaired reproductive function, anemia, etc.). We present a case of late diagnosis of celiac disease in a 15-year-old boy with physical (height SDS, -4.1; bone age SDS, -8.2) and sexual (Tanner 1) retardation. The negative results of gonadoliberin (max LH, 2 mIU/mL) and chorionic gonadotropin (Δ-testosterone, 2,3 nmol/L) tests indicated the lack of activation of the hypothalamo-pituitary-gonadal system. However, inhibin B (29.9 pg/mL) and anti-Mullerian hormone (43.8 ng/mL) levels indicated preservation of the reserve capabilities of this system. During follow-up, after treatment with a gluten-free diet for 10 months, the patient demonstrated an improved growth rate (2.7 SDS), progression of the sexual development stage (Tanner 2), and positive results of diagnostic diphereline (max LH, 16.8 IU/mL) and chorionic gonadotropin (Δ-testosterone, 11.8 nmol/L) tests. This case demonstrates the need to exclude celiac disease in patients with growth and sexual retardation, especially when these pathologies are combined with protein-energy deficiency, gastrointestinal symptoms, and anemia, as well as the need to use additional indicators of the reproductive system condition in boys, e.g. inhibin B and anti-Mullerian hormone.
- Open Access
- 4 May 2017
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 63 (2) , 114-116
Papillary thyroid cancer in an adolescent with a toxic single nodular goiter
The rate of nodular goiter in children ranges from 0.05 to 5.1%; in this case, the risk of thyroid cancer in childhood amounts to 3―70% of all cases of thyroid pathology. Therefore, the main issue is the differential diagnosis of a nosological variant of a thyroid nodule, which defines the optimal therapeutic tactics for a particular patient. The risk of malignancy is traditionally believed to be low in the case of decompensated functional autonomy of a thyroid nodule; therefore, the need for fine needle aspiration biopsy (FNAB) followed by cytomorphological analysis of the aspirate is avoided in most cases. The presented clinical case demonstrates papillary cancer in an adolescent with a toxic single nodular goiter. A thyroid ultrasound examination revealed a nodular lesion in the boy. An increase in the thyroid size and thyrotoxicosis manifestation occurred 3 years later. A cytomorphological study identified follicular neoplasia; scintigraphy revealed a hot nodule. Surgical treatment was planned. Antithyroid therapy was prescribed to prepare for surgery. After compensation of thyrotoxicosis, hemithyroidectomy was performed. A histological examination diagnosed papillary thyroid cancer, which required repeated thyroidectomy followed by radioiodine I131 ablation. The postoperative period was uneventful; the patient well tolerated suppressive levothyroxine therapy. Therefore, the presence of a toxic single nodular goiter does not exclude thyroid cancer, which defines the need to discuss the indications for FNAB of thyroid nodules in children.
- 4 May 2017
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 63 (2) , 114-116
Open AccessPapillary thyroid cancer in an adolescent with a toxic single nodular goiter
The rate of nodular goiter in children ranges from 0.05 to 5.1%; in this case, the risk of thyroid cancer in childhood amounts to 3―70% of all cases of thyroid pathology. Therefore, the main issue is the differential diagnosis of a nosological variant of a thyroid nodule, which defines the optimal therapeutic tactics for a particular patient. The risk of malignancy is traditionally believed to be low in the case of decompensated functional autonomy of a thyroid nodule; therefore, the need for fine needle aspiration biopsy (FNAB) followed by cytomorphological analysis of the aspirate is avoided in most cases. The presented clinical case demonstrates papillary cancer in an adolescent with a toxic single nodular goiter. A thyroid ultrasound examination revealed a nodular lesion in the boy. An increase in the thyroid size and thyrotoxicosis manifestation occurred 3 years later. A cytomorphological study identified follicular neoplasia; scintigraphy revealed a hot nodule. Surgical treatment was planned. Antithyroid therapy was prescribed to prepare for surgery. After compensation of thyrotoxicosis, hemithyroidectomy was performed. A histological examination diagnosed papillary thyroid cancer, which required repeated thyroidectomy followed by radioiodine I131 ablation. The postoperative period was uneventful; the patient well tolerated suppressive levothyroxine therapy. Therefore, the presence of a toxic single nodular goiter does not exclude thyroid cancer, which defines the need to discuss the indications for FNAB of thyroid nodules in children.
- Open Access
- 1 January 2017
- Published by Siberian State Medical University in Bulletin of Siberian Medicine
- Vol. 16 (3) , 87-96
Disorders of sex development 45,X/46,XY: clinical and laboratory characteristics of patients
Цель исследования. Изучить клинико-лабораторную характеристику пациентов с нарушением формирования пола (НФП) 45,Х/46,ХY. Материал и методы. В исследование включены 248 пациентов с неправильным строением наружных гениталий от раннего неонатального периода до 18 лет. По результатам цитогенетического и молекулярно-цитогенетического обследований сформирована группа пациентов с НФП, обусловленного мозаицизмом 45,Х/46,ХY. Проведена оценка антропометрических показателей, наружных и внутренних гениталий, гормональных показателей в мини-пубертате, нейтральном и пубертатном периодах, гистологическое исследование гонад, скрининг пороков развития. Результаты. НФП с кариотипом 46,ХY выявлено в 48% (120/248) случаев, с кариотипом 46,ХХ – в 38% (93/248), НФП с патологией половых хромосом – в 14% (35/248) наблюдений. Хромосомное НФП представлено следующими вариантами: синдромы Кляйнфельтера, Шерешевского – Ульриха – Тернера, химеризм, овотестикулярное, но большую часть составили пациенты с мозаицизмом 45,Х/46,ХY (65%). В группе пациентов с НФП 45,Х/46,ХY медиана cтепени маскулинизации наружных гениталий по шкале External Masculinization Score (EMS) составила 3 [1; 5,5]. Среди пороков развития наружных гениталий в большинстве случаев (82%, 18/22) имело место сочетание крипторхизма с гипоспадией. Дериваты Мюллеровых протоков выявлены у 91% (20/22) пациентов. Большая часть пациентов (77%) адаптируется в мужском паспортном поле. Не выявлено статистически значимых различий в строении наружных и внутренних гениталий между группами пациентов, адаптируемых в мужском и женском паспортном поле. При анализе гормональных показателей выявлена положительная корреляционная взаимосвязь между содержанием базального тестостерона в период мини-пубертата и индексом маскулинизации наружных гениталий по шкале EMS (р = 0,002; r = 0,9). В период мини-пубертата повышение уровня гонадотропных гормонов выявлено у 89% (8/9) детей, из которых сочетанное повышение лютеинизирующего гормона и фолликулостимулирующего гормона (ФСГ) отмечено в 33% (3/9), изолированное повышение ФСГ в 56% (5/9) случаев. В пубертатном периоде у 75% (3/4) пациентов выявлен гипергонадотропный гипогонадизм. По результатам гистологического исследования гонад отмечена гетерогенная картина. Гонады представлены различной степенью дисгенезии тестикулярной ткани: от легкой, близкой к гистологическому строению гонад при крипторхизме, до streak и овотестис. Среди внегонадных проявлений заболевания лидируют паховые грыжи (86%), пороки сердца (77%) и почек (36%). Патологическая задержка роста диагностирована у 23% детей. Выводы. В структуре заболевания на хромосомное НФП приходится 14% наблюдений. Группа пациентов с НФП 45,Х/46,ХY гетерогенна по степени дисгенезии гонад, строению наружных и внутренних половых органов.
- 1 January 2017
- Published by Siberian State Medical University in Bulletin of Siberian Medicine
- Vol. 16 (3) , 87-96
Open AccessDisorders of sex development 45,X/46,XY: clinical and laboratory characteristics of patients
Цель исследования. Изучить клинико-лабораторную характеристику пациентов с нарушением формирования пола (НФП) 45,Х/46,ХY. Материал и методы. В исследование включены 248 пациентов с неправильным строением наружных гениталий от раннего неонатального периода до 18 лет. По результатам цитогенетического и молекулярно-цитогенетического обследований сформирована группа пациентов с НФП, обусловленного мозаицизмом 45,Х/46,ХY. Проведена оценка антропометрических показателей, наружных и внутренних гениталий, гормональных показателей в мини-пубертате, нейтральном и пубертатном периодах, гистологическое исследование гонад, скрининг пороков развития. Результаты. НФП с кариотипом 46,ХY выявлено в 48% (120/248) случаев, с кариотипом 46,ХХ – в 38% (93/248), НФП с патологией половых хромосом – в 14% (35/248) наблюдений. Хромосомное НФП представлено следующими вариантами: синдромы Кляйнфельтера, Шерешевского – Ульриха – Тернера, химеризм, овотестикулярное, но большую часть составили пациенты с мозаицизмом 45,Х/46,ХY (65%). В группе пациентов с НФП 45,Х/46,ХY медиана cтепени маскулинизации наружных гениталий по шкале External Masculinization Score (EMS) составила 3 [1; 5,5]. Среди пороков развития наружных гениталий в большинстве случаев (82%, 18/22) имело место сочетание крипторхизма с гипоспадией. Дериваты Мюллеровых протоков выявлены у 91% (20/22) пациентов. Большая часть пациентов (77%) адаптируется в мужском паспортном поле. Не выявлено статистически значимых различий в строении наружных и внутренних гениталий между группами пациентов, адаптируемых в мужском и женском паспортном поле. При анализе гормональных показателей выявлена положительная корреляционная взаимосвязь между содержанием базального тестостерона в период мини-пубертата и индексом маскулинизации наружных гениталий по шкале EMS (р = 0,002; r = 0,9). В период мини-пубертата повышение уровня гонадотропных гормонов выявлено у 89% (8/9) детей, из которых сочетанное повышение лютеинизирующего гормона и фолликулостимулирующего гормона (ФСГ) отмечено в 33% (3/9), изолированное повышение ФСГ в 56% (5/9) случаев. В пубертатном периоде у 75% (3/4) пациентов выявлен гипергонадотропный гипогонадизм. По результатам гистологического исследования гонад отмечена гетерогенная картина. Гонады представлены различной степенью дисгенезии тестикулярной ткани: от легкой, близкой к гистологическому строению гонад при крипторхизме, до streak и овотестис. Среди внегонадных проявлений заболевания лидируют паховые грыжи (86%), пороки сердца (77%) и почек (36%). Патологическая задержка роста диагностирована у 23% детей. Выводы. В структуре заболевания на хромосомное НФП приходится 14% наблюдений. Группа пациентов с НФП 45,Х/46,ХY гетерогенна по степени дисгенезии гонад, строению наружных и внутренних половых органов.